From its inception, DNDi has advocated for increased resources for R&D for neglected diseases and for new and sustainable mechanisms to support this R&D. Moreover, DNDi is itself an example of a new form of international collaboration in health R&D that has successfully attracted new public and private funding to this field. Both to influence discussions on R&D financing at the WHO and in other fora and to support its own long-term funding strategy, DNDi has conducted an evaluation of existing and proposed R&D incentives and funding mechanisms, and developed an Outlook piece on the topic:
|“Financing & incentives for neglected disease R&D: Opportunities and challenges”, 2011|
|“Financing neglected disease R&D: principles and options” – based on an analysis from Paul Wilson, 2010|
The study has focused substantially but not exclusively on mechanisms that would strengthen the PDP model, either by directly funding PDPs, by filling gaps in the R&D spectrum that PDPs are not well suited to fill, or by creating stronger incentives for private and public sector firms to collaborate with PDPs. DNDi’s analysis has naturally focused on mechanisms that might support the development of new treatments for the “most neglected” diseases that are its primary focus, but many of the main conclusions apply to other diseases and product types.
This note describes the criteria that DNDi has used to assess R&D financing mechanisms and then outlines a few mechanisms that DNDi believes could fill important gaps in the current system.